226 related articles for article (PubMed ID: 22802221)
1. Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism.
Verdonk K; Durik M; Abd-Alla N; Batenburg WW; van den Bogaerdt AJ; van Veghel R; Roks AJ; Danser AH; van Esch JH
Hypertension; 2012 Sep; 60(3):722-9. PubMed ID: 22802221
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries.
Batenburg WW; Garrelds IM; Bernasconi CC; Juillerat-Jeanneret L; van Kats JP; Saxena PR; Danser AH
Circulation; 2004 May; 109(19):2296-301. PubMed ID: 15117835
[TBL] [Abstract][Full Text] [Related]
3. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation.
Moltzer E; Verkuil AV; van Veghel R; Danser AH; van Esch JH
Hypertension; 2010 Feb; 55(2):516-22. PubMed ID: 20026759
[TBL] [Abstract][Full Text] [Related]
4. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors.
Bergaya S; Hilgers RH; Meneton P; Dong Y; Bloch-Faure M; Inagami T; Alhenc-Gelas F; Lévy BI; Boulanger CM
Circ Res; 2004 Jun; 94(12):1623-9. PubMed ID: 15131008
[TBL] [Abstract][Full Text] [Related]
5. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
6. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
Li P; Ferrario CM; Brosnihan KB
J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
[TBL] [Abstract][Full Text] [Related]
7. Why do we need a selective angiotensin II type 2 receptor agonist?
Henrion D
Hypertension; 2012 Sep; 60(3):616-7. PubMed ID: 22802228
[No Abstract] [Full Text] [Related]
8. Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease.
van de Wal RM; van der Harst P; Wagenaar LJ; Wassmann S; Morshuis WJ; Nickenig G; Buikema H; Plokker HW; van Veldhuisen DJ; van Gilst WH; Voors AA
J Cardiovasc Pharmacol; 2007 Oct; 50(4):372-9. PubMed ID: 18049304
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
Fukuhara M; Neves LA; Li P; Diz DI; Ferrario CM; Brosnihan KB
J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo.
Brouwers S; Smolders I; Massie A; Dupont AG
Hypertension; 2013 Nov; 62(5):920-6. PubMed ID: 24041944
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors.
Ognibene DT; Oliveira PR; Marins de Carvalho LC; Costa CA; Espinoza LA; Criddle DN; Tano T; Soares de Moura R; Resende AC
Clin Exp Pharmacol Physiol; 2009 Jan; 36(1):12-9. PubMed ID: 18986337
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor?
van Esch JH; Oosterveer CR; Batenburg WW; van Veghel R; Jan Danser AH
Eur J Pharmacol; 2008 Jul; 588(2-3):286-93. PubMed ID: 18511032
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin AT
Fredgart MH; Leurgans TM; Stenelo M; Nybo M; Bloksgaard M; Lindblad L; De Mey JGR; Steckelings UM
Peptides; 2023 Jun; 164():170990. PubMed ID: 36894067
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II relaxations of bovine adrenal cortical arteries: role of angiotensin II metabolites and endothelial nitric oxide.
Gauthier KM; Zhang DX; Cui L; Nithipatikom K; Campbell WB
Hypertension; 2008 Jul; 52(1):150-5. PubMed ID: 18490519
[TBL] [Abstract][Full Text] [Related]
15. Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT(2)) receptor. Effects on neurite outgrowth in NG108-15 cells.
Guimond MO; Wallinder C; Alterman M; Hallberg A; Gallo-Payet N
Eur J Pharmacol; 2013 Jan; 699(1-3):160-71. PubMed ID: 23211679
[TBL] [Abstract][Full Text] [Related]
16. Lack of heterologous receptor desensitization induced by angiotensin II type 1 receptor activation in isolated normal rat thoracic aorta.
Pérez T; López RM; López P; Castillo C; Castillo EF
Vascul Pharmacol; 2011; 54(1-2):29-35. PubMed ID: 21122823
[TBL] [Abstract][Full Text] [Related]
17. β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats.
Del Borgo M; Wang Y; Bosnyak S; Khan M; Walters P; Spizzo I; Perlmutter P; Hilliard L; Denton K; Aguilar MI; Widdop RE; Jones ES
Clin Sci (Lond); 2015 Sep; 129(6):505-13. PubMed ID: 26186568
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats.
Bosnyak S; Welungoda IK; Hallberg A; Alterman M; Widdop RE; Jones ES
Br J Pharmacol; 2010 Feb; 159(3):709-16. PubMed ID: 20128808
[TBL] [Abstract][Full Text] [Related]
19. Hydrogen peroxide mediates a transient vasorelaxation with tempol during oxidative stress.
Chen Y; Pearlman A; Luo Z; Wilcox CS
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2085-92. PubMed ID: 17644566
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting physiological antagonism of calcitonin gene-related peptide towards endothelin-1 in rat mesenteric arteries and human coronary arteries.
Labruijere S; Compeer MG; van den Bogaerdt AJ; van den Brink AM; De Mey JG; Danser AH; Batenburg WW
Eur J Pharmacol; 2013 Nov; 720(1-3):303-9. PubMed ID: 24140435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
